Fresenius SE & Co. KGaA · XETR:FRE
Fresenius SE & Co. KGaA — Non-Deal Roadshow (October 2019)
43 slides from Fresenius SE & Co. KGaA's roadshow presentation, Oct 9, 2019
Slide 1: Roadshow Toronto
Roadshow Toronto Toronto, 9 October 2019 Frankfurt stock exchange: FRE │ US ADR program: FSNUY │ www.fresenius.com/investors
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive
Slide 3: A Global Leader In Health Care Products And Services
A Global Leader In Health Care Products And Services ~€33.5 bn in Sales Global presence in (as of Dec. 31, 2018) 100+ countries Total Shareholder Return: 10-year CAGR: ~15% Strong portfolio 288,000+ employees of products (30% of sales) worldwide and services (70% of sales) (as of June 30, 2019) Road
Slide 4: Strong and Balanced Health Care Portfolio
Strong and Balanced Health Care Portfolio Ownership: ~31% Ownership: 100% Ownership: 100% Ownership: 77% Dialysis Products Hospital Supplies Hospital Operation Projects and Services for Health Care Services Hospitals • Dialysis services • IV drugs • Acute care • Post-acute care • Hemodialysis produc
Slide 5: Total Shareholder Return – CAGR, Rounded
Total Shareholder Return – CAGR, Rounded 10 years 15 years 20 years 15% 14% 13% 12% 10% 9% 8% 8% 7% 6% 6% 4% DAX S&P 500 Fresenius MSCI World Fresenius DAX S&P 500 MSCI World Fresenius Fresenius DAX S&P 500 MSCI World Fresenius Fresenius Health Care Health Care Health Care Source: Bloomberg; dividen
Slide 6: Fresenius Medical Care: Global Dialysis Market Leader
Fresenius Medical Care: Global Dialysis Market Leader • The world’s leading provider of dialysis products Market Dynamics and services treating more than 339,000 patients1 in 3,996 clinics1 Global Dialysis Market 2018: • Provide highest standard of product quality and • ~€71 bn • ~6% patient growth
Slide 7: Fresenius Kabi: A Leading Global Hospital Supplier
Fresenius Kabi: A Leading Global Hospital Supplier • Comprehensive product portfolio for critically and Market Dynamics chronically ill patients • Strong Emerging Markets presence Global Addressable Market 2018: • Leading market positions in four product • ~€81 bn segments Growth Drivers: • Patent e
Slide 8: Fresenius Helios: Europe's Largest Private Hospital Operator – Helios Germany
Fresenius Helios: Europe’s Largest Private Hospital Operator Helios Germany • ~5%1 share in German acute care hospital Market Dynamics market • Organic growth based on growing number of German Acute Care Hospital Market: admissions and reimbursement rate increases • ~€102 bn2 • Ranks as quality lead
Slide 9: Fresenius Helios: Europe's Largest Private Hospital Operator – Helios Spain
Fresenius Helios: Europe’s Largest Private Hospital Operator Helios Spain • ~€3.0 bn sales in 2018 Market Dynamics • ~12%1 share in Spanish private hospital market Spanish Private Hospital Market: • Market leader in size and quality with excellent • ~€14 bn2 growth prospects Growth Drivers: • Broad
Slide 10: Fresenius Vamed: Leading Global Hospital Projects and Services Specialist
Fresenius Vamed: Leading Global Hospital Projects and Services Specialist • Manages hospital construction/expansion Market Dynamics projects and provides services for health care facilities worldwide Growth Drivers: • Offers project development, planning, turnkey • Emerging Market demand for buildin
Slide 11: Capital deployment centers on sustainable long-term value creation
Fresenius Group: Capital deployment centers on sustainable long-term value creation Re- Fuel organic growth with low-risk high- investments in return investments own business Short-term focus on small bolt-on Strategic acquisitions; long-term rigorous pursuit of acquisitions inorganic growth traject
Slide 12: Healthy Growth Targets 2020 - 2023
Fresenius Group: Healthy Growth Targets 2020 - 2023 Growing Markets with High Marketing of existing Attractive markets Entry Barriers value chain Strengthening and Attractive Product Pipeline Market consolidation extension of value chain Entry into attractive Development of post- Synergies biosimila
Slide 13: Healthy Growth Targets 2020 – 2023 (CAGRs)
Fresenius Group: Healthy Growth Targets 2020 – 2023 (CAGRs) Organic sales growth 4 – 7% (plus ~1% small to mid- size acquisitions) Organic net income1 growth 5 – 9% (plus ~1% small to mid- size acquisitions) 1 Net income attributable to shareholders of Fresenius SE & Co. KGaA Before special items Ro
Slide 14: Financial Review Q2/19
Financial Review Q2/19 Roadshow Toronto 2019 © Fresenius SE & Co. KGaA Investor Relations 14
Slide 15: Q2/19 Highlights
Q2/19 Highlights • Good organic sales growth across all business segments • Growth investments well on track • Fresenius Kabi: first biosimilar launched; continued excellent growth in Emerging Markets • Fresenius Helios: strong organic sales growth in Germany; acquisition of Cliníca Medellin in Colo
Slide 16: Fresenius Kabi: Update
Fresenius Kabi: Update IV Generics in North America • Conclusion of de-stocking during Q2/19 • Low single-digit price erosion in our base product portfolio • Intensified competition in certain molecules • Drug shortages: 36 end of Q2/19, unchanged from Q1/19; but fewer and less pronounced shortages
Slide 17: Fresenius Kabi: Update
Fresenius Kabi: Update Biosimilars • Successful launch of Idacio® in Germany, UK, Hungary, NL and Portugal • Roll-out of Idacio® in other EU countries well on track Clinical Nutrition • Continued dynamic growth of parenteral nutrition business • Start of production for enteral nutrition products in
Slide 18: Fresenius Helios: Update
Fresenius Helios: Update Helios Germany Further progress of investment Smart.Helios initiatives • Establishment of digital platform for rehab • FY target to hire 1,000 additional nursing aftercare of chronically ill patients staff already accomplished in H1/19; further • Acquisition of software prov
Slide 19: Fresenius Helios: Update
Fresenius Helios: Update Helios Spain Expansion in Spain Expansion in Latin America • Seville site expansion – additional 30 • Opportunistic market entry strategy beds, 2 additional surgery rooms, more progresses outpatient services; total investment of • Successful entry into Colombian market ~€20
Slide 20: Group: Q2/19 Key Financials
Fresenius Group: Q2/19 Key Financials €m Q2/191 IFRS 16 special Q2/19 Δ YoY cc1,2 effect items reported Sales 8,779 -18 - 8,761 6% EBIT 1,081 37 0 1,118 -7% Net interest -122 -58 1 -179 14% Income taxes -219 5 1 -213 9% Net income3 480 -9 0 471 0% Balance sheet total 59,342 5,587 - 64,929 Operating
Slide 21: Group: Q2/19 Business Segment Growth
Fresenius Group: Q2/19 Business Segment Growth Organic sales growth1 EBIT growth (cc)1 +4% -17% +4% +4% +5% -6% +27% +67% +5% -7% 1 On a comparable basis: Q2/18 adjusted for divestitures of Care Coordination activities at FMC; Q2/19 adjusted for IFRS 16 effect. All figures before special items Roads
Slide 22: Fresenius Kabi: Q2/19 Regional Highlights (1/2)
Fresenius Kabi: Q2/19 Regional Highlights (1/2) North America Europe • -1% organic growth • 1% organic growth • Conclusion of de-stocking during Q2/19 • Continued strong growth of enteral nutrition business • More competition for certain molecules • Product partnering business weighed on • Easing of
Slide 23: Fresenius Kabi: Q2/19 Regional Highlights (2/2)
Fresenius Kabi: Q2/19 Regional Highlights (2/2) Emerging Markets China: • 16% organic sales growth Asia-Pacific ex China: • 12% organic sales growth • Continued positive momentum Latin America/Africa: Total Emerging Markets • 13% organic sales growth FY/19 outlook increased: Clearly double-digit org
Slide 24: Fresenius Kabi: Q2 & H1/19 EBIT Growth
Fresenius Kabi: Q2 & H1/19 EBIT Growth €m Q2/19 Δ YoY cc H1/19 Δ YoY cc North America 233 0% 478 2% Margin 40.7% 60 bps 40.0% 120 bps Europe 79 -10% 166 -4% Margin 13.8% -200 bps 14.5% -100 bps Asia-Pacific/Latin 113 20% 217 19% America/Africa Margin 20.7% 120 bps 20.6% 130 bps Corporate and Corpora
Slide 25: Fresenius Helios: Q2/19 Highlights
Fresenius Helios: Q2/19 Highlights Helios Germany Helios Spain • Strong organic sales growth of 5% with a • Solid organic sales growth of 4% despite good case mix Easter being in Q2/19 • Continued good progress with preparatory • Excellent EBIT margin of 14.6% in H1/19 structural activities • Hot su
Slide 26: Fresenius Helios: Q2 & H1/19 Key Financials
Fresenius Helios: Q2 & H1/19 Key Financials €m Q2/19 Δ YoY H1/19 Δ YoY Total sales 2,349 0%/6%1 4,660 0%/5%1 Thereof Helios Germany 1,506 -3%/5%1 2,991 -4%/3%1 Thereof Helios Spain 842 6% 1,668 7% Total EBIT2 274 -6%/-4%1 540 -5%/-4%1 Margin 11.7% -80 bps 11.6% -60 bps Thereof Helios Germany 154 -8%
Slide 27: Fresenius Vamed
Fresenius Vamed • Strong H1/19 with 29% organic sales €m Q2/19 Δ YoY H1/19 Δ YoY growth • Vamed accelerates high-end service Total sales 467 76% 907 76% provision to Helios Germany and Spain Thereof organic sales 27%1 29%1 Service business 344 106% 676 109% 35%1 38%1 Project business 123 24% 231 21%
Slide 28: Group: Cash Flow
Fresenius Group: Cash Flow Operating CF1 Capex (net) Free Cash Flow1,2 €m Q2/19 LTM Margin Q2/19 LTM Margin Q2/19 LTM Margin 201 13.7% -165 -9.8% 36 3.9% 197 6.5% -76 -4.8% 121 1.7%3 -42 4.7% -5 -1.7% -47 3.0% Corporate/Other -33 n.a. -16 n.a. -49 n.a. Excl. FMC 433 9.4%4 -262 -6.9% 171 2.5%4 1,023
Slide 29: Group: 2019 Financial Outlook by Business Segment
Fresenius Group: 2019 Financial Outlook by Business Segment FY/18 H1/19 FY/191 €m (except otherwise stated) Base Actual FY/19e1 New Sales growth (org) 6,544 4% 3% - 6% EBIT growth (cc) 1,1392 6% 3% - 6% Sales growth (org) 8,993 4% 2% - 5% EBIT growth 1,052 -5% -5% to -2% Sales growth (org) 1,688 29%
Slide 30: Group: 2019 Financial Guidance
Fresenius Group: 2019 Financial Guidance €m FY/18 H1/19 FY/19e2 (except otherwise stated) Base1 Actual2 FY/19e2 New Sales growth (cc) 33,009 6% 3% - 6% 4% - 7% Net income3 1,872 0% ~0% growth (cc) 1 Before special items and after adjustments 2 Excluding transaction-related expenses, revaluations of
Slide 31: Attachments
Attachments Roadshow Toronto 2019 © Fresenius SE & Co. KGaA Investor Relations 31
Slide 32: Group: Leverage Ratio
Fresenius Group: Leverage Ratio Net Debt/EBITDA target 2019 4,00 4.0 Around the upper-end of self-imposed target 3.5 3,50 corridor of 2.5 – 3.0 x3 2 3.22 3.21 2 3.09 2.98 3,00 3.0 3.00 2.97 2.98 2.84 2.80 2.75 2.71 2.67 2.65 2,50 2.5 2.55 2.53 2.33 2,00 1 2011 2012 2013 2014 2015 2016 Q1 Q2 Q3 Q4 Q1
Slide 33: Fresenius Kabi: Organic Sales Growth by Regions
Fresenius Kabi: Organic Sales Growth by Regions Δ YoY Δ YoY €m Q2/19 organic H1/19 organic North America 573 -1% 1,196 -1% Europe 572 1% 1,145 2% Asia-Pacific/Latin 546 14% 1,051 14% America/Africa Asia-Pacific 374 15% 715 13% Latin America/Africa 172 13% 336 15% Total sales 1,691 4% 3,392 4% Roadsh
Slide 34: Fresenius Kabi: Organic Sales Growth by Product Segment
Fresenius Kabi: Organic Sales Growth by Product Segment Δ YoY Δ YoY €m Q2/19 organic H1/19 organic IV Drugs 711 1% 1,456 0% Infusion Therapy 206 -1% 413 2% Clinical Nutrition 471 11% 924 9% Medical Devices/ 303 7% 599 9% Transfusion Technology Total sales 1,691 4% 3,392 4% Roadshow Toronto 2019 © Fr
Slide 35: Fresenius Helios: Key Metrics
Fresenius Helios: Key Metrics H1/19 FY/18 Δ No. of hospitals Helios Germany 86 86 0% - Acute care hospitals 83 83 0% No. of hospitals Helios Spain 50 47 6% (Hospitals) No. of beds Helios Germany 29,356 29,329 0% - Acute care hospitals 28,829 28,802 0% No. of beds Helios Spain 7,126 7,019 2% (Hospita
Slide 36: Attachments
Attachments Roadshow Toronto 2019 © Fresenius SE & Co. KGaA Investor Relations 36
Slide 37: FY/18 base for Fresenius Group Guidance FY/19
FY/18 base for Fresenius Group Guidance FY/19 €m Sales reported 33,530 Divestitures of Care Coordination activities at FMC (H1/18) -521 Sales basis for growth rates 33,009 Net income reported 2,027 Transaction Costs, Akorn, Biosimilars 25 Bridge Financing Costs Akorn 12 Revaluations of Biosimilars c
Slide 38: FY/18 base for Fresenius Medical Care Outlook FY/19
FY/18 base for Fresenius Medical Care Outlook FY/19 €m Sales reported 16,547 Divestitures of Care Coordination activities at FMC (H1/18) -521 Sales basis for growth rates 16,026 Net income reported 1,982 Impact of FCPA related charge 28 Gain related to divestitures of Care Coordination activities -6
Slide 39: FY/18 base for Fresenius Kabi Outlook FY/19
FY/18 base for Fresenius Kabi Outlook FY/19 €m Sales basis for growth rates 6,544 Transaction Costs Akorn, Biosimilars 34 Revaluations of Biosimilars contingent liabililties 7 EBIT (before special items = base for Kabi guidance) 1,139 The special items are reported in the Group Corporate/Other segme
Slide 40: IFRS 16: Profit and Loss - Implications
IFRS 16: Profit and Loss - Implications €m Expected IFRS 16 effect on 2019 Sales - ~€0.1 bn (discontinuation of sale-leaseback transactions at FMC NA) EBITDA + ~€1.0 bn (fewer rent expenses) Depreciation and amortization - ~€0.9 bn (additional depreciation) EBIT + ~€0.1 bn Interest - ~€0.2 bn (addit
Slide 41: IFRS 16: Balance Sheet
IFRS 16: Balance Sheet €m Expected IFRS 16 effect on 2019 Right-of-use-asset ~€5.2 bn Lease liability ~€5.5 bn Equity ~-€0.3 bn Leverage + ~30-40 bps Leases have to be recognized as a right-of-use-asset and corresponding liability Roadshow Toronto 2019 © Fresenius SE & Co. KGaA Investor Relations 41
Slide 42: 26th Consecutive Dividend Increase
Fresenius Group: 26th Consecutive Dividend Increase CAGR +16% 0.75 0.80 0.62 0.55 0.32 0.37 0.42 0.44 € 0.29 0.23 0.25 0.22 0.19 0.16 0.02 '93 '05 '06 '07 '08 '09 '10 '11 '12 '13 '14 '15 '16 '17 '18 Dividend growth aligned to EPS growth Pay-out ratio: 24% Roadshow Toronto 2019 © Fresenius SE & Co. K
Slide 43: Financial Calendar / Contact
Financial Calendar / Contact Financial Calendar 29 October 2019 Results Q3/19 Please note that these dates could be subject to change. Contact Investor Relations Fresenius SE & Co. KGaA phone: +49 6172 608-2485 e-mail: ir-fre@fresenius.com For further information and current news: www.fresenius.com
Fresenius SE & Co. KGaA — Non-Deal Roadshow (October 2019) on 6ix